This site uses optional cookies which are currently not set, but will be if you visit another page. Find out more about the cookies we use

 
 

27Feb

Accelerating Cancer Drug Development - From target to patients

Location: Alderley Park Conference Centre, Alderley Park, Cheshire


Focusing upon the strengths in the discovery, development and manufacture of cancer medicines in the North of England through to commercialisation (patients), this event will highlight industry, academic and clinical strengths whilst showcasing key activities, infrastructure and the joined up translational environment which exists in the North.

We are delighted to have Susan Galbraith, Vice President of Oncology at AstraZeneca and Rob Bristow, Director of MCRC and Chief Academic Officer at The Christie NHS Foundation Trust as Keynote Speakers.

Gold Sponsor: Thermo Fisher

Conference Programme

Time

Session

Speakers

08.30 - 09.00

Arrival and Registration


09.00 - 09.05

Welcome Address

Geoff Davison, CEO, Bionow

09.05 - 09.35

Keynote Speaker

Susan Galbraith, Vice President - Oncology, AstraZeneca

09.35 - 11.05

Parallel Sessions
New Target Identification & Chemistry

Chair: Tilly Bingham, Redx Pharma

A Tale of One City. Hit-Finding Adventures Against Undruggable Targets...
Allan Jordan, Head of Chemistry, CRUK
Cliff Jones, Head of Chemistry, Redx Pharma
Tailoring Screening Libraries for Neuro-Oncology using Multiparameter Optimisation
Thomas Pesnot, Group Leader (Medicinal Chemistry) Concept Life Sciences
Caroline Springer, Director of Drug Discovery, CRUK

 

09.35 - 11.05

Parallel Sessions
Preclinical: Pharmacology, Biomarkers and Toxicology

Chair: Jane Kendrew, Alderley Park Limited

Preclinical Safety Evaluation: Lost in Translation?
Richard Knight, Director, ApconiX
Improving the Predictive Value of Preclinical Work in Oncology Drug Discovery
Nicolas Floch, Associate Principal Scientist, AstraZeneca 
Enabling Capabilities in SME Oncology Drug Discovery
Peter Simpson, Chief Scientific Officer, Medicines Discovery Catapult

Juliana Maynard, Head of Imaging Services Alderley Imaging, Alderley Park

11.05 - 11.35

Coffee, Networking & Exhibition

11.35 - 12.20

Clinical Trials and How Clinical Decisions are Made

Chair: Steve McConchie, Aptus Clinical 

Glen Clack, Honorary Professor of Translational Medicine, University of Sheffield
Natalie Cook, Senior Clinical Lecturer in Experimental Cancer Medicine, The Christie

12.20 - 12.40

Patients Perspective

Jim Elliot, Independent Cancer Patients Voice

12.40 - 13.50

Lunch, Networking & Exhibition

13.50 - 14.20

Keynote Speaker

Rob Bristow, Director MCRC and Chief Academic Officer, The Christie

14.20 - 15.35

Parallel Sessions
Pharmaceutical Development

Chair: Paul Dickinson, Seda Pharmaceutical Development Solutions

Accelerating the Pharmaceutical Development of New Cancer Therapies
Paul Stott, Vice President Global Product Development, AstraZeneca
Drug Development Product: Considerations for FiM Studies
Mike Frodsham, Pharmaceutical Development Officer, Quay Pharma
Novel Drug Delivery in Oncology
Marianne Ashford, Senior Pharmaceutical Scientist,  AstraZeneca

14.20 - 15.35  

Parallel Sessions
Moving Towards an Era of Personalised
Medicine

Chair: Caroline Phillips, Redx Pharma

Caroline Dive, Deputy Director, CRUK
Angela Silmon, Chief Executive Officer, NewGene
Huw Ricketts, Director - Business Development, Partnering for Precision Diagnostics, QIAGEN

15.35 - 16.45

Panel Discussion
What is the Future for Cancer Research? 

Chair: Mike Ward, Informa / Pharma Intelligence Insights Portfolio

Rob Bristow, Director MCRC and Chief Academic Officer, The Christie
Peter Simpson, Chief Scientific Officer, Medicines Discovery Catapult
Ruth Roberts, Director & Co-founder, ApconiX
Ian Hickson, Professor of Drug Discovery Bioscience, Newcastle University
Johnson Y.N. Lau, Chief Executive Officer, Athenex

16.45

Close

 

Delegate Fees
Premium Member: £125.00 + VAT
Member: £155.00 + VAT
Non-Member: £155.00 + VAT

> Register here